Estrella Immunopharma Stock Fundamentals
| ESLA Stock | 0.99 0.04 3.88% |
Estrella Immunopharma fundamentals help investors to digest information that contributes to Estrella Immunopharma's financial success or failures. It also enables traders to predict the movement of Estrella Stock. The fundamental analysis module provides a way to measure Estrella Immunopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Estrella Immunopharma stock.
At present, Estrella Immunopharma's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Other Operating Expenses is expected to grow to about 8.8 M, whereas Depreciation And Amortization is forecasted to decline to about 246.2 K. Estrella | Select Account or Indicator |
Estrella Immunopharma Company Shares Outstanding Analysis
Estrella Immunopharma's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Estrella Immunopharma Shares Outstanding | 36.18 M |
Most of Estrella Immunopharma's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Estrella Immunopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Estrella Shares Outstanding Historical Pattern
Today, most investors in Estrella Immunopharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Estrella Immunopharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Estrella Immunopharma shares outstanding as a starting point in their analysis.
Estrella Immunopharma Shares Outstanding |
| Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Estrella Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, Estrella Immunopharma has 36.18 M of shares currently outstending. This is 79.96% lower than that of the Biotechnology sector and 66.14% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 93.67% higher than that of the company.
Estrella Immunopharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Estrella Immunopharma's current stock value. Our valuation model uses many indicators to compare Estrella Immunopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Estrella Immunopharma competition to find correlations between indicators driving Estrella Immunopharma's intrinsic value. More Info.Estrella Immunopharma is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers . At present, Estrella Immunopharma's Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Estrella Immunopharma's earnings, one of the primary drivers of an investment's value.Estrella Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Estrella Immunopharma's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Estrella Immunopharma could also be used in its relative valuation, which is a method of valuing Estrella Immunopharma by comparing valuation metrics of similar companies.Estrella Immunopharma is currently under evaluation in shares outstanding category among its peers.
Estrella Fundamentals
| Return On Equity | -1.63 | ||||
| Return On Asset | -0.35 | ||||
| Current Valuation | 15.43 M | ||||
| Shares Outstanding | 36.18 M | ||||
| Shares Owned By Insiders | 72.08 % | ||||
| Shares Owned By Institutions | 0.80 % | ||||
| Number Of Shares Shorted | 4.87 K | ||||
| Price To Book | 49.93 X | ||||
| EBITDA | (7.31 M) | ||||
| Net Income | (7.31 M) | ||||
| Total Debt | 180.7 K | ||||
| Book Value Per Share | 0.02 X | ||||
| Cash Flow From Operations | (16.07 M) | ||||
| Short Ratio | 0.93 X | ||||
| Earnings Per Share | (0.24) X | ||||
| Beta | 0.41 | ||||
| Market Capitalization | 53.91 M | ||||
| Total Asset | 4.45 M | ||||
| Retained Earnings | (19.5 M) | ||||
| Working Capital | 4.27 M | ||||
| Net Asset | 4.45 M |
About Estrella Immunopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Estrella Immunopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Estrella Immunopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Estrella Immunopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Estrella Immunopharma is a strong investment it is important to analyze Estrella Immunopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Estrella Immunopharma's future performance. For an informed investment choice regarding Estrella Stock, refer to the following important reports:Check out Estrella Immunopharma Piotroski F Score and Estrella Immunopharma Altman Z Score analysis. For information on how to trade Estrella Stock refer to our How to Trade Estrella Stock guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Estrella Immunopharma. If investors know Estrella will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Estrella Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Estrella Immunopharma is measured differently than its book value, which is the value of Estrella that is recorded on the company's balance sheet. Investors also form their own opinion of Estrella Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Estrella Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Estrella Immunopharma's market value can be influenced by many factors that don't directly affect Estrella Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Estrella Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Estrella Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Estrella Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.